AffaMed Therapeutics rakes in over $170m Series B

AffaMed Therapeutics, a global clinical-stage biopharmaceutical company, has raised over $170 million in Series B financing.

30 March 2021•1 min read
Feature image
LinkedInXEmail
LinkedInXEmail

Related articles